glp-1 receptor agonist type 1 diabetes randomized trial Agonists as Treatments for 2 Current Insights, Advantages and Challenges
Description
An emphasis was placed on post-marketing surveillance informed by pre-marketing safety signals and on comorbid conditions that are common in T2DM patients, including: cardiovascular disease, chronic kidney disease, and older age
[DOI] [PubMed] [Google Scholar] Zhang X
If drugs to mitigate nausea (or other GI AEs) are needed for over a month when the maintenance GLP-1 RA dose has been reached, a dose reduction should be considered for the patient to tolerate the drug with no need for pharmacological support [35]
Olof Eriksson, Director PET imaging at Antaros and Associate Professor at Uppsala University comments: We are very proud of this collaboration between Antaros Medical and Sanofi
Bacteria have even more time to ferment sulfur-containing compounds
More serious but less common adverse effects require clinical vigilance
